ImmuSmol Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

ImmuSmol General Information

Description

Developer of antibodies intended for staining applications for lab tests and immunoassay development. The company's product targets small or low-molecular-weight molecules and is used in research, diagnostic, and therapeutic applications, enabling healthcare professionals to visualize, quantify, and modulate monoclonal antibodies interfering with endogenous small molecules involved in cancer and central nervous system disorders.

Contact Information

Website
www.immusmol.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 229 Cours de L'Argonne
  • 33000 Bordeaux
  • France
+33 05
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 229 Cours de L'Argonne
  • 33000 Bordeaux
  • France
+33 05

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuSmol Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Jan-2026 Completed Generating Revenue
3. Grant 01-Apr-2018 Completed Generating Revenue
2. Early Stage VC 23-Sep-2014 $649K $853K Completed Generating Revenue
1. Accelerator/Incubator 29-Jul-2014 $203K $203K Completed Generating Revenue
To view ImmuSmol’s complete valuation and funding history, request access »

ImmuSmol Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

ImmuSmol Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4659023-A1 Method of predicting success of a cancer therapy Pending 03-Feb-2023
US-20260235610-A1 Method of predicting success of a cancer therapy Pending 03-Feb-2023
WO-2024161038-A1 Method of predicting success of a cancer therapy Inactive 03-Feb-2023
GB-201511291-D0 Agent which increases and/or mimics kynurenine and optional combination thereof with an immunotherapeutic Inactive 26-Jun-2015
WO-2016193499-A1 Immunomodulatory antibody or immunotherapeutic, agent which increases and/or mimicks kynurenine, and optional combination thereof Inactive 05-Jun-2015 C07K16/2818
To view ImmuSmol’s complete patent history, request access »

ImmuSmol Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

ImmuSmol FAQs

  • When was ImmuSmol founded?

    ImmuSmol was founded in 2012.

  • Where is ImmuSmol headquartered?

    ImmuSmol is headquartered in Bordeaux, France.

  • What is the size of ImmuSmol?

    ImmuSmol has 12 total employees.

  • What industry is ImmuSmol in?

    ImmuSmol’s primary industry is Discovery Tools (Healthcare).

  • Is ImmuSmol a private or public company?

    ImmuSmol is a Private company.

  • What is ImmuSmol’s current revenue?

    The current revenue for ImmuSmol is .

  • How much funding has ImmuSmol raised over time?

    ImmuSmol has raised $853K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process